Kim K. Birtcher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kim K. Birtcher has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Ali Mortazavi
Department of Pharmacy, Kelsey‐Seybold Clinic, Houston, Texas
1 shared publicationChristopher P. Cannon
1 shared publicationGary K. Rice
Department of Pharmacy, Kelsey‐Seybold Clinic, Houston, Texas
1 shared publicationGray Ellrodt
1 shared publication- Gregg Fonarow
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
1 shared publication Kenneth A. LaBresh
1 shared publication
Latest Publications
- 20 November 2014
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 17 (1) , 1-7
When Compliance Is an Issue—How to Enhance Statin Adherence and Address Adverse Effects
Cardiovascular disease is prevalent and costly. Interventions and therapies that reduce morbidity and mortality associated with cardiovascular disease could have an enormous impact on clinical and economic outcomes. Statins reduce atherosclerotic cardiovascular disease-related morbidity and mortality; however, adherence to statins is less than optimal. It is important for clinicians as well as health plan managers to be aware of the patient- and insurance plan-specific factors that have been shown to influence adherence. Perceived statin-related side effects may also decrease adherence. Statin-related myalgia may be difficult to distinguish from myalgia caused by other conditions, and statin therapy may be discontinued unnecessarily in patients who would otherwise benefit. It is imperative that clinicians work closely with patients to improve adherence to statin therapy and be knowledgable in managing potential statin-related side effects.
- 20 November 2014
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 17 (1) , 1-7
When Compliance Is an Issue—How to Enhance Statin Adherence and Address Adverse Effects
Cardiovascular disease is prevalent and costly. Interventions and therapies that reduce morbidity and mortality associated with cardiovascular disease could have an enormous impact on clinical and economic outcomes. Statins reduce atherosclerotic cardiovascular disease-related morbidity and mortality; however, adherence to statins is less than optimal. It is important for clinicians as well as health plan managers to be aware of the patient- and insurance plan-specific factors that have been shown to influence adherence. Perceived statin-related side effects may also decrease adherence. Statin-related myalgia may be difficult to distinguish from myalgia caused by other conditions, and statin therapy may be discontinued unnecessarily in patients who would otherwise benefit. It is imperative that clinicians work closely with patients to improve adherence to statin therapy and be knowledgable in managing potential statin-related side effects.
- 1 September 2010
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 9 (3) , 103-112
Performance Achievement Award Program for Get With The Guidelines Coronary Artery Disease Is Associated With Global and Sustained Improvement in Cardiac Care for Patients Hospitalized With an Acute Myocardial Infarction
Adherence to evidence-based guidelines for the treatment of coronary artery disease (CAD) is suboptimal. Our goal was to determine whether the performance achievement award program for Get With The Guidelines—Coronary Artery Disease (GWTG-CAD) was associated with global and sustained adherence to evidence-based guidelines for acute myocardial infarction. Adherence to evidence-based guidelines was assessed in 170,061 hospitalized acute myocardial infarction patients from 418 US hospitals participating in GWTG-CAD from 2000 to 2008. Hospitals that received a performance achievement award by attaining 85% adherence with 6 GWTG performance measures for at least 12 consecutive months were compared with those that had enrolled in the GWTG-CAD and had not attained this level of adherence. The outcome measures were change in adherence for 6 GWTG performance measures, 9 GWTG quality measures, a composite score, and an all-or-none measure. Generalized estimating equations were used to provide valid inference accounting for the within site correlation. Hospitals that maintained 85% adherence with GWTG performance measures for at least 12 consecutive months had a higher composite score (94.78 ± 15.99% vs. 89.72 ± 21.37, P < 0.0001) and an all-or-none measure (87.17% vs. 75.15%, P < 0.0001) compared with hospitals that had not yet attained this level of adherence. Hospital adherence with performance and quality measures generally improved over time. In conclusion, the performance achievement award program for GWTG-CAD was associated with global and sustained adherence to evidence-based guidelines. Our data suggest that this tool is a useful component of a quality improvement initiative and should be considered for other similar programs.
- 1 September 2010
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 9 (3) , 103-112
Performance Achievement Award Program for Get With The Guidelines Coronary Artery Disease Is Associated With Global and Sustained Improvement in Cardiac Care for Patients Hospitalized With an Acute Myocardial Infarction
Adherence to evidence-based guidelines for the treatment of coronary artery disease (CAD) is suboptimal. Our goal was to determine whether the performance achievement award program for Get With The Guidelines—Coronary Artery Disease (GWTG-CAD) was associated with global and sustained adherence to evidence-based guidelines for acute myocardial infarction. Adherence to evidence-based guidelines was assessed in 170,061 hospitalized acute myocardial infarction patients from 418 US hospitals participating in GWTG-CAD from 2000 to 2008. Hospitals that received a performance achievement award by attaining 85% adherence with 6 GWTG performance measures for at least 12 consecutive months were compared with those that had enrolled in the GWTG-CAD and had not attained this level of adherence. The outcome measures were change in adherence for 6 GWTG performance measures, 9 GWTG quality measures, a composite score, and an all-or-none measure. Generalized estimating equations were used to provide valid inference accounting for the within site correlation. Hospitals that maintained 85% adherence with GWTG performance measures for at least 12 consecutive months had a higher composite score (94.78 ± 15.99% vs. 89.72 ± 21.37, P < 0.0001) and an all-or-none measure (87.17% vs. 75.15%, P < 0.0001) compared with hospitals that had not yet attained this level of adherence. Hospital adherence with performance and quality measures generally improved over time. In conclusion, the performance achievement award program for GWTG-CAD was associated with global and sustained adherence to evidence-based guidelines. Our data suggest that this tool is a useful component of a quality improvement initiative and should be considered for other similar programs.
- 1 May 2007
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (5) , 729-733
Pharmacist‐Managed Vaccination Program Increased Influenza Vaccination Rates in Cardiovascular Patients Enrolled in a Secondary Prevention Lipid Clinic
Study Objectives. To determine whether a vaccination program in a pharmacist‐managed secondary prevention lipid clinic increased influenza immunization rates in a high‐risk population, and whether age or gender disparity existed among those vaccinated.Design. Retrospective chart review.Setting. Large, multispecialty group practice.Patients. A total of 476 and 266 patients seen at clinic visits during the 2003–2004 and 2004–2005 influenza seasons, respectively.Measurements and Main Results. Immunization rates were compared before (2003–2004 influenza season) and after (2004–2005 influenza season) the implementation of the influenza vaccination program; χ2 analysis was used for all statistical inferences. Vaccination rates increased significantly from 39% to 76% (pConclusion. The pharmacist‐managed program increased influenza vaccination rates in high‐risk patients with cardiovascular disease in advance of the newly published secondary prevention guidelines. Age‐related differences in the vaccination rates were eliminated after program implementation.
- 1 May 2007
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (5) , 729-733
Pharmacist‐Managed Vaccination Program Increased Influenza Vaccination Rates in Cardiovascular Patients Enrolled in a Secondary Prevention Lipid Clinic
Study Objectives. To determine whether a vaccination program in a pharmacist‐managed secondary prevention lipid clinic increased influenza immunization rates in a high‐risk population, and whether age or gender disparity existed among those vaccinated.Design. Retrospective chart review.Setting. Large, multispecialty group practice.Patients. A total of 476 and 266 patients seen at clinic visits during the 2003–2004 and 2004–2005 influenza seasons, respectively.Measurements and Main Results. Immunization rates were compared before (2003–2004 influenza season) and after (2004–2005 influenza season) the implementation of the influenza vaccination program; χ2 analysis was used for all statistical inferences. Vaccination rates increased significantly from 39% to 76% (pConclusion. The pharmacist‐managed program increased influenza vaccination rates in high‐risk patients with cardiovascular disease in advance of the newly published secondary prevention guidelines. Age‐related differences in the vaccination rates were eliminated after program implementation.